News
New survey seeks women’s views on reproductive health
The information from the survey is hoped to inform current and future government decision-making and health policy in England
The UK government has launched a new survey in a bid to encourage women to share their views on reproductive health.
Women across England are being encouraged to help “shape” future reproductive health policy by sharing their experiences of a range of issues, including periods, contraception, fertility, pregnancy and menopause.
Findings from the survey will then be used to better understand women’s reproductive health experiences over time. The information is hoped to inform current and future government decision-making and health policy.
“Women and girls deserve the best healthcare at every stage of their lives, but we simply cannot deliver that without listening to their lived experiences and concerns,” said minister for women’s health strategy, Maria Caulfield.
“Women should always have a say in their own healthcare, whether that’s in managing pregnancy and fertility or dealing with the challenges of the menopause in the workplace.
“I would encourage every woman to complete the survey on reproductive health as soon as they’re able and ensure their voice is heard.”
Women’s health ambassador, Professor Dame Lesley Regan, said: “We need to make healthcare work for women and girls – and for it to fit around their lives. There’s no point bolstering services if they cannot be accessed, or the support available does not work for them and meet their needs.
“That’s why we’re asking women and girls to share their experience, whether it’s about periods, menopause or endometriosis. We need your voice to shape a new system of healthcare that gives women what they need.”
Dr Rebecca French, associate professor of sexual and reproductive health research at the London School of Hygiene and Tropical Medicine, added: “For most women, it can be nearly 40 years from their first period to menopause.
“Throughout this time, women should be able to make informed decisions about their own reproductive health and wellbeing, such as if and when to get pregnant and where to access appropriate support and treatment.
“Women have previously described difficulties accessing reproductive health services – for example, to get contraceptive supplies, to access fertility treatment or to obtain an appointment with a gynaecologist. Often health services are not ‘joined up’, leading to multiple visits and appointment delays.
“We know that poor reproductive health not only has a negative effect on health in general but can also impact women’s mental health, relationships and finances,” she continued.
“Further research is needed to better understand inequalities across England so that women and people described as female at birth are able to make the choices they need for their own reproductive health and wellbeing.
“The Women’s Reproductive Health Survey provides an opportunity to better understand what support is needed and how these issues can best be addressed.”
The survey is open to all women in England aged 16 to 55 years and will run for six weeks from September 7.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






